News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
Heidelberg Pharma AG reports financial figures, business performance in 2025, and outlook for 2026, including CEO appointment, cost-cutting program, and extended cash runway. Fast Track designation for HDP-101 by FDA -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
Heidelberg Pharma to receive milestone payment from partner Huadong for clinical study with HDP-101 in China. First patient dosed in Phase I study evaluating safety, tolerability, and efficacy -